Similar articles

Abstract: Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males. Immune-checkpoint inhibitors (ICIs) that target programmed cell death protein-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) have achieved impressive efficacy in the treatment of non-small-cell lung cancer (NSCLC) (Pardoll, 2012; Champiat et al., 2016; Gao et al., 2022). Although ICIs are usually well tolerated, they are often accompanied by immune-related adverse events (irAEs) (Doroshow et al., 2019). Non-specific activation of the immune system produces off-target immune and inflammatory responses that can affect virtually any organ or system (O'Kane et al., 2017; Puzanov et al., 2017). Compared with adverse events caused by chemotherapy, irAEs are often characterized by delayed onset and prolonged duration and can occur in any organ at any stage of treatment, including after cessation of treatment (Puzanov et al., 2017; von Itzstein et al., 2020). They range from rash, pneumonitis, hypothyroidism, enterocolitis, and autoimmune hepatitis to cardiovascular, hematological, renal, neurological, and ophthalmic irAEs (Nishino et al., 2016; Kumar et al., 2017; Song et al., 2020). Hence, we conducted a retrospective study to identify validated factors that could predict the magnitude of the risk of irAEs in patients receiving PD-1/PD-L1 inhibitors; our approach was to analyze the correlation between the clinical characteristics of patients at the start of treatment and relevant indicators such as hematological indices and the risk of developing irAEs. Then, we developed an economical, practical, rapid, and simple model to assess the risk of irAEs in patients receiving ICI treatment, as early as possible.

建立和验证非小细胞肺癌PD-1/PD-L1抑制剂相关不良反应的风险预测模型

[1]BiswasT, KangKH, GawdiR, et al., 2020. Using the systemic immune-inflammation index (SII) as a mid-treatment marker for survival among patients with stage-III locally advanced non-small cell lung cancer (NSCLC). Int J Environ Res Public Health, 17(21):7995.

[2]Castelo-BrancoC, SoveralI, 2014. The immune system and aging: a review. Gynecol Endocrinol, 30(1):16-22.

[3]ChampiatS, LambotteO, BarreauE, et al., 2016. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol, 27(4):559-574.

[4]CortelliniA, ChiariR, RicciutiB, et al., 2019. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer, 20(4):237-247.e1.

[5]CortelliniA, BersanelliM, SantiniD, et al., 2020. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer, 128:17-26.

[6]DalyLE, PowerDG, O'ReillyÁ, et al., 2017. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer, 116(3):310-317.

[7]DeurenbergP, YapM, van StaverenWA, 1998. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes, 22(12):1164-1171.

[8]DoroshowDB, SanmamedMF, HastingsK, et al., 2019. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res, 25(15):4592-4602.

[9]DvorakHF, 2015. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy. Cancer J, 21(4):237-243.

[10]EunY, KimIY, SunJM, et al., 2019. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep, 9:14039.

[11]GaoZR, LingX,Shi CYY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.

[12]GeorgiadisMS, SteinbergSM, HankinsLA, et al., 1995. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst, 87(5):361-366.

[13]HuB, YangXR, XuY, et al., 2014. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res, 20(23):6212-6222.

[14]HuangYQ, SoonYY, AminkengF, et al., 2022. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. Int J Cancer, 150(4):636-644.

[15]KugelCH III, DouglassSM, WebsterMR, et al., 2018. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res, 24(21):5347-5356.

[16]KumarV, ChaudharyN, GargM, et al., 2017. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol, 8:49.

[17]LiNL, 2016. Platelets in cancer metastasis: to help the “villain” to do evil. Int J Cancer, 138(9):2078-2087.

[18]MailletD, CorbauxP, StelmesJJ, et al., 2020. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer, 132:61-70.

[19]MantovaniA, AllavenaP, SicaA, et al., 2008. Cancer-related inflammation. Nature, 454(7203):436-444.

[20]MirsoianA, MurphyWJ, 2015. Obesity and cancer immunotherapy toxicity. Immunotherapy, 7(4):319-322.

[21]NishinoM, Giobbie-HurderA, HatabuH, et al., 2016. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol, 2(12):1607-1616.

[22]O'KaneGM, LabbéC, DohertyMK, et al., 2017. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist, 22(1):70-80.

[23]PardollDM, 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4):252-264.

[24]PawelecG, 2018. Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma? Clin Cancer Res, 24(21):5193-5194.

[25]PengLH, WangY, LiuF, et al., 2020. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother, 69(9):1813-1822.

[26]PuzanovI, DiabA, AbdallahK, et al., 2017. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 5(1):95.

[27]SongP, ZhangDD, CuiXX, et al., 2020. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer, 11(9):2406-2430.

[28]von ItzsteinMS, KhanS, GerberDE, 2020. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem, 66(6):779-793.

[29]WangQ, LiSB, QiaoSM, et al., 2021. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front Immunol, 12:648652.

[30]ZamoraC, RiudavetsM, AngueraG, et al., 2021. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunol Immunother, 70(6):1691-1704.